Skip to main content
Emcure Pharmaceuticals Limited logo

Emcure Pharmaceuticals Limited — Investor Relations & Filings

Ticker · EMCURE ISIN · INE168P01015 LEI · 335800WYB6OIBY9EOZ42 BSE.NS Manufacturing
Open in API
Filings indexed 201 across all filing types
Latest filing 2025-11-10 Regulatory Filings
Country IN India
Listing BSE.NS EMCURE

About Emcure Pharmaceuticals Limited

https://www.emcure.com

Emcure Pharmaceuticals Limited is a research-driven global pharmaceutical organization engaged in the development, manufacturing, and marketing of a broad range of differentiated pharmaceutical products. The company maintains a diverse portfolio across several key therapeutic areas, including gynaecology, cardiovascular, oncology, anti-infectives, and HIV/AIDS. With a strong emphasis on research and development, Emcure operates multiple state-of-the-art manufacturing facilities and R&D centers globally. Its business model focuses on complex generics and innovative formulations, serving healthcare needs in over 70 countries. The company is recognized for its vertically integrated operations and commitment to high-quality standards, catering to both regulated and emerging markets worldwide.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing a strategic partnership between Novo Nordisk India and Emcure Pharma to commercialize a pharmaceutical product (Poviztra®) in India. It contains no financial statements, regulatory filings, or detailed financial data. It is not an earnings release, annual report, or any form of regulatory filing. The document is informational and promotional in nature, typical of a press release. Therefore, it fits best under the category of a general Regulatory Filing (RNS) as a miscellaneous announcement that does not fit other specific categories.
2025-11-10 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal communication from Emcure Pharmaceuticals Limited to stock exchanges notifying about an upcoming earnings call scheduled for November 11, 2025, to discuss the company's unaudited financial results for Q2 FY26. It includes details about the call timing, dial-in numbers, and mentions that the transcript and audio recording will be made available later. The document does not contain actual financial data or results but is an announcement of the earnings call event. According to the classification rules, such a notification about an earnings call is best classified as a Call Transcript (CT) category, as it relates directly to the earnings call event. However, since this document is only an intimation of the earnings call and does not contain the transcript itself, it is more appropriate to classify it as a Regulatory Filing (RNS) because it is a regulatory announcement about the earnings call, not the transcript or the earnings release itself. The document length is short (2308 characters), and it is an announcement rather than the report or transcript itself. Therefore, the best fit is Regulatory Filings (RNS).
2025-11-03 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-11-03 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges informing about a scheduled Board Meeting to approve unaudited financial results for the quarter and half-year ended September 30, 2025. It references regulatory compliance under SEBI Listing Obligations and Disclosure Requirements. The document does not contain the financial results themselves, only an intimation of the upcoming board meeting where results will be approved. The document length is short (2223 characters), and it serves as a notification rather than a report. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement rather than an Interim Report (IR) or Earnings Release (ER).
2025-11-03 English
Credit Rating- Revision
Capital/Financing Update Classification · 95% confidence The document is a formal communication addressed to stock exchanges regarding a revision in credit rating by CRISIL for Emcure Pharmaceuticals Limited. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is an update on credit rating changes, not a financial report, earnings release, or management discussion. The document length is short (1824 characters) and it is an announcement of a credit rating update, which fits best under Capital/Financing Update (CAP) as it relates to the company's financing conditions and creditworthiness. It is not a report or detailed financial statement, so it is not 10-K, IR, or ER. It is not a regulatory filing in the fallback sense, as it specifically discloses a credit rating revision, which is a financing update.
2025-10-17 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a short notification addressed to stock exchanges regarding a US FDA inspection at the company's manufacturing facility. It references compliance with SEBI Listing Regulations, specifically Regulation 30, which pertains to disclosure of material events. The document states the inspection concluded without any observation and requests the information be taken on record. There is no financial data, no detailed report, no voting results, no management discussion, or other substantive content typical of financial or regulatory reports. The document is an announcement of an event (inspection outcome) rather than a report or detailed filing. Given the short length (1717 characters) and nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-10-10 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.